Cardiovascular Drugs Practice Questions

Q: Which antianginal drug can be safely used with drugs used for treatment of erectile dysfunction?

pFOX inhibitor. **Explanation:** The core clinical concern when combining antianginal drugs with erectile dysfunction (ED) medications (PDE-5 inhibitors like Sildenafil) is the risk of **severe, life-threatening hypotension**. **1. Why pFOX Inhibitors are correct:** pFOX (partial Fatty Acid Oxidation) inhibitors, primarily **Trimetazidine**, work by shifting the myocardial metabolism from fatty acid oxidation to glucose oxidation. This metabolic shift requires less oxygen to produce ATP, protecting the ischemic myocardium without affecting hemodynamics. Since pFOX inhibitors do not cause vasodilation or affect the Nitric Oxide (NO)-cGMP pathway, they do not interact with PDE-5 inhibitors and are safe to use concurrently. **2. Why the other options are incorrect:** * **Nitrates (Option D):** These are strictly contraindicated. Nitrates increase cGMP production, while PDE-5 inhibitors prevent cGMP breakdown. This synergistic effect leads to massive cGMP accumulation, causing profound systemic vasodilation and fatal hypotension. * **Potassium Channel Openers (Option C):** Drugs like **Nicorandil** have a dual mechanism; they open K+ channels and also possess a nitrate-like moiety. They can significantly potentiate the hypotensive effects of PDE-5 inhibitors. * **Calcium Channel Blockers (Option A):** While not strictly contraindicated like nitrates, CCBs (especially dihydropyridines) cause vasodilation. Combining them with PDE-5 inhibitors requires extreme caution due to the additive risk of hypotension. **High-Yield Clinical Pearls for NEET-PG:** * **Ranolazine:** Another antianginal that inhibits the late sodium current ($I_{Na}$); it is also hemodynamically neutral and safe with ED drugs. * **Ivabradine:** A pure heart rate reducer (Funny current inhibitor) that is also safe to combine. * **Time Gap:** If a patient on Sildenafil requires nitrates, a minimum gap of **24 hours** is mandatory (48 hours for Tadalafil).

Q: Which of the following statements about digoxin is false?

Dosage reduction is required in hepatic disease.. **Explanation:** The correct answer is **A**, as digoxin is primarily eliminated by the kidneys, not the liver. **1. Why Option A is False (The Correct Answer):** Digoxin is a polar glycoside with a unique pharmacokinetic profile. Approximately **60-80% of the drug is excreted unchanged in the urine** via glomerular filtration and P-glycoprotein secretion. Since it does not undergo significant hepatic metabolism, its clearance is independent of liver function. Therefore, dosage reduction is **not** required in hepatic disease. **2. Why the other options are True:** * **Option B:** Because digoxin is primarily renally excreted, its half-life (normally 36–40 hours) increases significantly in **renal failure**, leading to toxicity. Dose adjustment based on creatinine clearance is mandatory. * **Option C:** Digoxin has **parasympathomimetic (vagotonic) effects**, which slow the conduction through the AV node and decrease the heart rate. This makes it useful in controlling ventricular rate in atrial fibrillation but can cause symptomatic bradycardia. * **Option D:** Digoxin is a **positive inotrope**. It inhibits the Na+/K+-ATPase pump, leading to an increase in intracellular sodium, which subsequently increases intracellular calcium via the Na+/Ca2+ exchanger. This enhances the force of myocardial contraction. **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** Digoxin Immune Fab (Digibind). * **Electrolyte Interactions:** **Hypokalemia**, hypomagnesemia, and hypercalcemia predispose to digoxin toxicity. * **ECG Changes:** The earliest sign of toxicity is often PVCs; the most characteristic sign is the "Reverse Tick" or "Sagging" ST-segment depression. * **Drug Interactions:** Quinidine, Verapamil, and Amiodarone increase digoxin levels by displacing it from tissue binding sites and reducing renal clearance.

Q: Nicotinic acid is useful in all types of hyperlipoproteinemias, EXCEPT:

Type-I. **Explanation:** Nicotinic acid (Niacin) is a broad-spectrum hypolipidemic agent that acts by inhibiting **hormone-sensitive lipase** in adipose tissue. This reduces the breakdown of triglycerides into free fatty acids (FFAs). Since FFAs are the primary substrate for hepatic VLDL synthesis, Niacin effectively lowers VLDL, and subsequently its metabolite, LDL. **Why Type-I is the Correct Answer:** * **Type-I Hyperlipoproteinemia (Familial Chylomicronemia)** is characterized by a deficiency in **Lipoprotein Lipase (LPL)** or its cofactor, ApoC-II. This leads to a massive accumulation of **Chylomicrons** in the plasma. * Niacin does not significantly affect the clearance of dietary chylomicrons; its primary mechanism is reducing endogenous VLDL production. Therefore, it is ineffective in treating Type-I. **Why the other options are incorrect:** * **Type-II (Familial Hypercholesterolemia):** Niacin reduces LDL levels by decreasing VLDL synthesis and inhibiting hepatic diacylglycerol acyltransferase-2. It is a potent agent for lowering LDL (Type-IIa) and VLDL (Type-IIb). * **Type-III (Dysbetalipoproteinemia):** Niacin helps reduce IDL (Remnant particles) by decreasing the precursor VLDL. * **Type-IV (Familial Hypertriglyceridemia):** Niacin is highly effective here as it directly inhibits VLDL secretion, which is the hallmark of Type-IV. **High-Yield Clinical Pearls for NEET-PG:** * **Most Potent Effect:** Niacin is the most effective drug for **increasing HDL levels** (by decreasing HDL catabolism). * **Lp(a) Reduction:** It is one of the few drugs that significantly lowers **Lipoprotein(a)**. * **Side Effects:** The most common side effect is **cutaneous flushing** (mediated by Prostaglandin $D_2$ and $E_2$), which can be prevented by taking **Aspirin** 30 minutes prior. * **Metabolic Risks:** It can cause **hyperuricemia** (precipitating gout) and **hyperglycemia** (acanthosis nigricans is a rare sign of insulin resistance here).

Q: Which antihypertensive is a prodrug and is converted to its active form in the brain?

Methyldopa. **Explanation:** **Methyldopa** is the correct answer because it is a centrally acting antihypertensive that functions as a **prodrug**. After crossing the blood-brain barrier, it is taken up by noradrenergic neurons and converted via the catecholamine synthesis pathway: * Methyldopa → α-methyldopamine → **α-methylnorepinephrine** (the active metabolite). This active form stimulates central **α₂-adrenergic receptors** in the nucleus tractus solitarius, leading to a decrease in sympathetic outflow and a subsequent fall in blood pressure. **Analysis of Incorrect Options:** * **Clonidine:** While also a central α₂-agonist, it is **not a prodrug**. It is active in its original form and directly stimulates the receptors. * **Minoxidil:** This is a potent vasodilator (K⁺ channel opener). While it is a prodrug, it is converted to its active form (minoxidil sulfate) in the **liver**, not the brain. * **Nitroprusside:** This is a direct-acting vasodilator that releases nitric oxide (NO) spontaneously in the blood; it does not require metabolic activation in the brain. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Methyldopa remains a preferred antihypertensive in **pregnancy** (Gestational Hypertension/Preeclampsia). * **Adverse Effects:** Can cause a **positive Direct Coombs Test** (hemolytic anemia), sedation, and drug-induced lupus-like syndrome. * **Mechanism Tip:** Remember "False Neurotransmitter" – α-methylnorepinephrine replaces NE in vesicles but acts as a potent agonist only at inhibitory α₂ receptors.

Q: What is the drug of choice for managing an asthmatic patient with hypertension?

Amlodipine. ### Explanation **Correct Answer: D. Amlodipine** **1. Why Amlodipine is the Drug of Choice:** In patients with **Bronchial Asthma**, the primary goal is to avoid any medication that can trigger bronchospasm. Amlodipine is a **Dihydropyridine Calcium Channel Blocker (CCB)**. It works by causing peripheral vasodilation without affecting the bronchial smooth muscle. Unlike beta-blockers, CCBs do not interfere with $\beta_2$ receptors in the lungs, making them safe and effective for hypertensive patients with co-existing respiratory diseases like asthma or COPD. **2. Why Other Options are Incorrect:** * **Propranolol (Option B):** This is a **non-selective beta-blocker**. It blocks both $\beta_1$ (heart) and $\beta_2$ (bronchioles) receptors. Blocking $\beta_2$ receptors leads to life-threatening bronchoconstriction in asthmatics. It is strictly contraindicated. * **Timolol (Option A):** Also a non-selective beta-blocker. Even when used as eye drops for glaucoma, systemic absorption can trigger severe asthma attacks. * **Metoprolol (Option C):** This is a **cardioselective ($\beta_1$) blocker**. While "safer" than propranolol, selectivity is dose-dependent and is lost at higher doses. In clinical practice and exams, even selective beta-blockers are generally avoided in asthmatics if safer alternatives like CCBs or ACE inhibitors are available. **3. NEET-PG High-Yield Pearls:** * **Preferred Antihypertensives in Asthma:** CCBs (Amlodipine), ACE inhibitors (though watch for "ACE-cough"), and ARBs (Losartan). * **Beta-blocker Contraindications:** Asthma, COPD, 2nd/3rd-degree heart block, and Prinzmetal angina. * **Drug of Choice for Hypertension with Diabetes:** ACE inhibitors (Renoprotective). * **Drug of Choice for Hypertension in Pregnancy:** Labetalol (followed by Methyldopa/Nifedipine).

Q: Acute symptomatic sinus bradycardia usually responds to which of the following medications?

Atropine. **Explanation:** **1. Why Atropine is Correct:** Atropine is the **first-line drug** for acute symptomatic bradycardia. It is a competitive **muscarinic antagonist** that blocks the action of acetylcholine at the M2 receptors in the Sinoatrial (SA) node. By inhibiting the parasympathetic (vagal) tone, it increases the firing rate of the SA node and enhances conduction through the Atrioventricular (AV) node, thereby increasing the heart rate. **2. Why Other Options are Incorrect:** * **Adrenaline (Epinephrine):** While it has potent $\beta_1$ agonist activity that increases heart rate, it is typically reserved for cardiac arrest or as a second-line infusion if atropine and pacing fail. * **Dopamine:** This is a second-line treatment option. It is used as an infusion for bradycardia associated with hypotension, but it is not the initial drug of choice. * **Norepinephrine:** It primarily acts on $\alpha_1$ receptors causing vasoconstriction. While it has some $\beta_1$ activity, the resulting increase in blood pressure often triggers a **reflex bradycardia**, making it unsuitable for treating slow heart rates. **3. NEET-PG High-Yield Pearls:** * **Standard Dose:** 0.5 mg IV every 3–5 minutes (Maximum total dose: 3 mg). * **Paradoxical Effect:** Doses of atropine **< 0.5 mg** can cause "paradoxical bradycardia" due to the blockade of presynaptic inhibitory M1 receptors on vagal nerve endings. * **Ineffectiveness:** Atropine is often ineffective in patients with **Heart Transplants** (denervated hearts) and **Type II Second-degree or Third-degree AV blocks** (where pacing is preferred). * **Drug of Choice for AV block in MI:** Atropine is specifically preferred for bradycardia/AV block occurring in **Inferior Wall MI** (due to high vagal tone).

Q: Which of the following antilipidemic drugs reduces cholesterol levels by decreasing cholesterol absorption in the intestine by acting on NPC1L1 receptors?

Fenofibrate. **Explanation:** The question asks for the drug that inhibits cholesterol absorption via the **NPC1L1 (Niemann-Pick C1-Like 1)** protein. **Note on the Answer Key:** There appears to be a discrepancy in the provided key. **Ezetimibe (Option D)** is the classic and specific inhibitor of the NPC1L1 transporter. **Fenofibrate (Option A)** is a PPAR-α agonist and does not act on NPC1L1. **1. Why Ezetimibe is the correct mechanism-based answer:** Ezetimibe selectively inhibits the **NPC1L1 receptor** located on the brush border of enterocytes in the small intestine. This action blocks the absorption of both dietary and biliary cholesterol. By reducing the delivery of intestinal cholesterol to the liver, it upregulates LDL receptors, leading to a reduction in serum LDL-C levels. **2. Why the other options are incorrect:** * **Fenofibrate (Option A):** A Fibrate that activates **PPAR-α** (Peroxisome Proliferator-Activated Receptor-alpha). Its primary effect is to increase LPL (Lipoprotein Lipase) activity, significantly lowering triglycerides. * **Nicotinic Acid (Option B):** Inhibits the lipolysis of triglycerides in adipose tissue by acting on G-protein coupled receptors, thereby reducing VLDL and LDL synthesis. * **Lovastatin (Option C):** A Statin that competitively inhibits **HMG-CoA reductase**, the rate-limiting enzyme in hepatic cholesterol synthesis. **High-Yield NEET-PG Pearls:** * **Ezetimibe** is often used as an "add-on" to statin therapy (synergistic effect). * **NPC1L1** is the specific molecular target for Ezetimibe. * **Side Effects:** Ezetimibe is generally well-tolerated but may cause reversible hepatic impairment when combined with statins. * **Drug of Choice for Hypertriglyceridemia:** Fibrates (like Fenofibrate). * **Drug of Choice for Hypercholesterolemia:** Statins.

Q: Which enzymes activate prodrugs of ACE inhibitors to their active form?

Esterases. **Explanation:** Most ACE inhibitors (ACEIs) are formulated as **prodrugs** to improve their oral bioavailability and lipid solubility. These prodrugs are esters that require metabolic activation to become pharmacologically active. **1. Why Esterases are correct:** The conversion of an ACE inhibitor prodrug (e.g., Enalapril) into its active metabolite (e.g., Enalaprilat) occurs primarily in the **liver** via **hepatic esterases**. These enzymes hydrolyze the ester bond, releasing the active carboxylic acid form which can then bind to the Angiotensin Converting Enzyme. **2. Analysis of Incorrect Options:** * **Amidases:** These enzymes hydrolyze amide bonds. While important for the metabolism of drugs like Lidocaine, they are not involved in the activation of ACEI prodrugs. * **Angiotensin Converting Enzyme (ACE):** This is the *target* of the drug, not the activator. ACEIs inhibit this enzyme to prevent the conversion of Angiotensin I to Angiotensin II. * **Conjugases:** These are involved in Phase II metabolism (e.g., glucuronidation) to make drugs more water-soluble for excretion, rather than the initial activation of prodrugs. **High-Yield Clinical Pearls for NEET-PG:** * **The Exceptions:** All ACE inhibitors are prodrugs **EXCEPT Captopril and Lisinopril**. These two are already active and do not require hepatic activation (useful in patients with severe liver disease). * **Active Metabolites:** Enalapril → Enalaprilat; Ramipril → Ramiprilat; Perindopril → Perindoprilat. * **Excretion:** Most ACEIs are excreted renally. **Fosinopril** and **Moexipril** are unique as they have significant biliary excretion, making them safer in patients with renal impairment. * **Side Effects:** Remember the mnemonic **CAPTOPRIL** (Cough, Angioedema, Proteinuria, Taste changes, Orthostatic hypotension, Pregnancy contraindication, Renal artery stenosis contraindication, Increased potassium, Leukopenia).

Q: Which of the following is NOT a contraindication for digitalis therapy?

Increased intracellular calcium. **Explanation:** Digitalis (Digoxin) works by inhibiting the **Na⁺/K⁺-ATPase pump**, which indirectly leads to an **increase in intracellular calcium** levels. This increase in calcium is the fundamental mechanism responsible for its positive inotropic effect (increased force of contraction). Therefore, increased intracellular calcium is the *intended therapeutic goal*, not a contraindication. **Analysis of Contraindications:** * **Carditis (Option A):** In conditions like acute rheumatic carditis, the myocardium is highly irritable. Digitalis can precipitate severe arrhythmias in an inflamed heart, making it a relative contraindication. * **Atrioventricular (AV) Block (Option C):** Digitalis has potent vagomimetic effects and directly slows conduction through the AV node. In patients with pre-existing heart block, it can worsen the condition, potentially leading to complete heart block. * **Hepatic Failure (Option D):** While Digoxin is primarily excreted renally, **Digitoxin** (another cardiac glycoside) is metabolized by the liver. In the context of general digitalis therapy, hepatic or renal impairment requires extreme caution or avoidance to prevent toxicity due to the drug's narrow therapeutic index. **High-Yield Clinical Pearls for NEET-PG:** * **Hypokalemia** is the most common electrolyte abnormality that predisposes to digitalis toxicity (as K⁺ and Digoxin compete for the same binding site on the Na⁺/K⁺-ATPase pump). * **Hypercalcemia** and **Hypomagnesemia** also increase the risk of digitalis-induced arrhythmias. * **Wolff-Parkinson-White (WPW) Syndrome** is a classic contraindication as digitalis can shorten the refractory period of the accessory pathway, leading to fatal ventricular rates. * **Digibind** (Digoxin-specific antibody fragments) is the antidote for life-threatening toxicity.

Question 1

Which antianginal drug can be safely used with drugs used for treatment of erectile dysfunction?

Accepted Answer

pFOX inhibitor

Answer

Calcium channel blockers

Answer

Potassium channel opener

Answer

Nitrates

Question 2

Which of the following statements about digoxin is false?

Accepted Answer

Dosage reduction is required in hepatic disease.

Answer

Dosage reduction is required in renal failure.

Answer

It can cause bradycardia.

Answer

It increases the force of contraction in congestive heart failure.

Question 3

Nicotinic acid is useful in all types of hyperlipoproteinemias, EXCEPT:

Accepted Answer

Type-I

Answer

Type-II

Answer

Type-III

Answer

Type-IV

Question 4

Which antihypertensive is a prodrug and is converted to its active form in the brain?

Accepted Answer

Methyldopa

Answer

Clonidine

Answer

Minoxidil

Answer

Nitroprusside

Question 5

What is the drug of choice for managing an asthmatic patient with hypertension?

Accepted Answer

Amlodipine

Answer

Timolol

Answer

Propranolol

Answer

Metoprolol

Question 6

The beneficial effects of nitrates in the treatment of angina include the following except?

Accepted Answer

Decreased diastole perfusion time

Answer

Decreased arterial pressure

Answer

Decreased ventricular volume

Answer

Decreased ejection time

Question 7

Acute symptomatic sinus bradycardia usually responds to which of the following medications?

Accepted Answer

Atropine

Answer

Adrenaline

Answer

Dopamine

Answer

Norepinephrine

Question 8

Which of the following antilipidemic drugs reduces cholesterol levels by decreasing cholesterol absorption in the intestine by acting on NPC1L1 receptors?

Accepted Answer

Fenofibrate

Answer

Nicotinic acid

Answer

Lovastatin

Answer

Ezetimibe

Question 9

Which enzymes activate prodrugs of ACE inhibitors to their active form?

Accepted Answer

Esterases

Answer

Amidases

Answer

Angiotensin converting enzyme

Answer

Conjugases

Question 10

Which of the following is NOT a contraindication for digitalis therapy?

Accepted Answer

Increased intracellular calcium

Answer

Carditis

Answer

Atrioventricular block

Answer

Hepatic failure

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?